Loading...
Low-dose aspirin (LDA) provides demonstrated benefit for secondary prevention of cardiovascular (CV) events, but a possible benefit for primary prevention remains unproven. LDA therapy is also associated with an increased risk for upper gastrointestinal bleeding (UGIB), and various factors affect that risk. To aid clinicians in therapeutic decision-making, investigators developed a calculator to estimate the relative CV benefit and GI risk of LDA therapy in individual patients.
Researchers based the risk for cardiac events on 10-year event estimates from the Framingham Heart Study and the risk for UGIB on a baseline estimate of 1 event per 1000 person-years with adjustment for documented risks associated with individual factors. Sensitivity …